{"nctId":"NCT03977727","briefTitle":"FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump","startDateStruct":{"date":"2019-06-11","type":"ACTUAL"},"conditions":["Type 1 Diabetes Mellitus"],"count":40,"armGroups":[{"label":"Fiasp/Novolog","type":"EXPERIMENTAL","interventionNames":["Drug: Fiasp®","Drug: Novolog®","Device: 670G hybrid closed loop continuous subcutaneous insulin infusion system"]},{"label":"Novolog/Fiasp","type":"EXPERIMENTAL","interventionNames":["Drug: Fiasp®","Drug: Novolog®","Device: 670G hybrid closed loop continuous subcutaneous insulin infusion system"]}],"interventions":[{"name":"Fiasp®","otherNames":[]},{"name":"Novolog®","otherNames":["Aspart"]},{"name":"670G hybrid closed loop continuous subcutaneous insulin infusion system","otherNames":["Medtronic 670G pump"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial\n2. Male or female, age ≥18 years at the time of signing informed consent\n3. Documented diagnoses of T1DM ≥1 year prior to the day of screening\n4. Using the Medtronic pump Minimed 670G for CSII in a basal-bolus regimen with a rapid acting insulin analogue for at least 30 days prior to screening and willing to continue using their personal Medtronic Minimed 670G and CSII for insulin treatment throughout the trial.\n5. Ability and willingness to use the same insulin infusion sets throughout the trial\n6. Using the same insulin for at least 30 days prior to screening\n7. HbA1c \\< 8.5% as assessed by local laboratory at screening\n8. BMI ≤ 35.0 kg/m2 at screening\n9. Ability and willingness to adhere to the protocol including performing SMPG profiles, attending visits, utilizing the auto mode feature of the pump for at least 80 % of the time during the study, and completing meal tests\n\nExclusion Criteria:\n\n1. Known or suspected hypersensitivity to trial products or related products\n2. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice)\n3. Participation in another clinical trial within 28 days before the screening visit. Note: clinical trials do not include non-interventional studies\n4. Anticipated significant change in lifestyle (e.g. eating, exercise or sleeping pattern) throughout the trial\n5. Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischemic attack within the past 180 days prior to the day of screening\n6. Subjects classified as being in New York Heart Association (NYHA) Class IV at screening\n7. Planned coronary, carotid or peripheral artery revascularization known on the day of screening.\n8. Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic\n\n   ≥180 mmHg or diastolic ≥110 mmHg) at screening\n9. Impaired liver function, defined as ALT ≥ 2.5 times upper normal limit at screening\n10. Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of \\< 45 ml/min/1.73 m2\n11. Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism in the opinion of the Investigator\n12. Proliferative retinopathy or maculopathy requiring acute treatment at the time of screening\n13. History of hospitalization for ketoacidosis ≤180 days prior to the day of screening\n14. Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 30 days before screening\n15. Presence of malignant neoplasms at the time of screening. Basal and squamous cell skin cancer and any carcinoma in-situ is allowed.\n16. Reoccurring Severe hypoglycemia while on the Medtronic Minimed 670G in the investigators opinion\n17. Any condition which, in the opinion of the Investigator, might jeopardize Subject's safety or compliance with the protocol\n\n    \\-","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"1-Hour Change in Postprandial Plasma Glucose (PPG)","description":"Change was calculated as the PPG value at 1 hour minus the PPG value at baseline (time -2 minutes) during meal test","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105.15","spread":"56.73"},{"groupId":"OG001","value":"154.24","spread":"54.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.90","spread":"82.70"},{"groupId":"OG001","value":"114.94","spread":"61.14"}]}]}]},{"type":"SECONDARY","title":"2-Hour Change in Postprandial Plasma Glucose (PPG)","description":"Change was calculated as the value at 2 hour minus the value at baseline during meal test","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.55","spread":"90.62"},{"groupId":"OG001","value":"65.00","spread":"57.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.10","spread":"92.55"},{"groupId":"OG001","value":"104.53","spread":"80.57"}]}]}]},{"type":"SECONDARY","title":"Percentage of Time Spent Between Below 70 mg/dL","description":"Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":"1.48"},{"groupId":"OG001","value":"1.72","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":"1.62"},{"groupId":"OG001","value":"2.03","spread":"1.36"}]}]}]},{"type":"SECONDARY","title":"Percentage of Time Spent Between 70 mg/dL and 180 mg/dL","description":"Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.80","spread":"8.08"},{"groupId":"OG001","value":"73.67","spread":"6.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.28","spread":"8.12"},{"groupId":"OG001","value":"75.04","spread":"5.95"}]}]}]},{"type":"SECONDARY","title":"Percentage of Time Spent Above 200 mg/dL","description":"Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.90","spread":"6.90"},{"groupId":"OG001","value":"15.44","spread":"5.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.57","spread":"7.85"},{"groupId":"OG001","value":"14.11","spread":"4.43"}]}]}]},{"type":"SECONDARY","title":"Percentage of Time Spent in Hypoglycemia (40 mg/dL - 54 mg/dL)","description":"Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".46","spread":".53"},{"groupId":"OG001","value":".40","spread":".48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".50","spread":".50"},{"groupId":"OG001","value":".35","spread":".36"}]}]}]},{"type":"SECONDARY","title":"Percentage of Time Spent in Severe Hypoglycemia (> 40 mg/dL)","description":"Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"1,5 Anhydroglucitol Levels","description":"1,5 anhydroglucitol levels were measured on the 6th week of each therapy","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.50","spread":"3.37"},{"groupId":"OG001","value":"7.12","spread":"3.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.28","spread":"3.54"},{"groupId":"OG001","value":"6.95","spread":"3.31"}]}]}]},{"type":"SECONDARY","title":"Fructosamine Levels","description":"Cumulative glycemic control expressed in fructosamine levels (micromol/Liter) were measured on the 6th week of each therapy","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"322.60","spread":"42.24"},{"groupId":"OG001","value":"296.35","spread":"31.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"305.40","spread":"32.28"},{"groupId":"OG001","value":"314.31","spread":"28.97"}]}]}]},{"type":"SECONDARY","title":"HbA1c","description":"Cumulative glycemic control expressed in HbA1c% measured on the 6th week of each therapy","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.09","spread":".47"},{"groupId":"OG001","value":"7.00","spread":".31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.09","spread":".44"},{"groupId":"OG001","value":"6.88","spread":".33"}]}]}]},{"type":"SECONDARY","title":"Insulin Use - Change in Daily Dose","description":"Change was calculated as the value on the last day of therapy minus the value on the 1st day of therapy in each period","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"7.45"},{"groupId":"OG001","value":".29","spread":"13.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"11.80"},{"groupId":"OG001","value":"-2.65","spread":"9.13"}]}]}]},{"type":"SECONDARY","title":"Insulin Use - Bolus","description":"Change in %bolus insulin (units) as the value on the last day of therapy minus the value on the 1st day of therapy in each period","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.54","spread":"6.54"},{"groupId":"OG001","value":"-4.32","spread":"7.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.83","spread":"7.62"},{"groupId":"OG001","value":"-1.34","spread":"5.35"}]}]}]},{"type":"SECONDARY","title":"Insulin Use - Basal","description":"Change in %basal insulin (units) as the value on the last day of therapy minus the value on the 1st day of therapy in each period","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":"6.54"},{"groupId":"OG001","value":"4.32","spread":"7.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.83","spread":"7.62"},{"groupId":"OG001","value":"1.34","spread":"5.35"}]}]}]},{"type":"SECONDARY","title":"Insulin Use - Automatic Basal Insulin","description":"Average amount per day (units) calculated for each participant under each therapy","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".87","spread":".307"},{"groupId":"OG001","value":"1.20","spread":".65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".86","spread":".32"},{"groupId":"OG001","value":"1.20","spread":".66"}]}]}]},{"type":"SECONDARY","title":"Insulin Pump - Active Insulin Time","description":"Average time per day (hours) calculated for each participant under each therapy","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":".06"},{"groupId":"OG001","value":"3","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"0"},{"groupId":"OG001","value":"3","spread":".02"}]}]}]},{"type":"SECONDARY","title":"Insulin Pump - Auto Mode","description":"Percentage of time spent in auto-mode after calibration under each therapy","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.28","spread":"6.42"},{"groupId":"OG001","value":"89.31","spread":"8.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.17","spread":"11.43"},{"groupId":"OG001","value":"87.2","spread":"15.6"}]}]}]},{"type":"SECONDARY","title":"Insulin Pump - Manual Mode","description":"Percentage of time spent in manual-mode after calibration under each therapy","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.72","spread":"6.42"},{"groupId":"OG001","value":"10.69","spread":"8.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.45","spread":"11.44"},{"groupId":"OG001","value":"12.8","spread":"15.6"}]}]}]},{"type":"SECONDARY","title":"Change in Carbohydrate Ratio","description":"Change was calculated as the carbohydrate ratio on the last day of therapy minus the carbohydrate ratio on the 1st day of therapy in each period","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-.27","spread":"1.09"},{"groupId":"OG001","value":"-.02","spread":".47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-.14","spread":".95"},{"groupId":"OG001","value":".2","spread":".76"}]}]}]},{"type":"SECONDARY","title":"Infusion Site Reactions","description":"Number of Infusion site reactions reported by patient","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Pump Occlusions","description":"Number of Occlusion events reported by patient","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":19},"commonTop":["Common Cold","Gasteroenteritis","Bronchitis","erythema at infusion site","Non Proliferative Diabetic Retinopathy"]}}}